13F GuideFiling Basics
What is SEC Form 13F? Ultimate Guide to Institutional Equity Filings
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
AlphaSMO Research GuideRead Guide
CIK: 0001652044
Total reported value
$99.1B
$99.1B
42 檔
1.3%
The Q2 2024 SEC filing reveals that Alphabet Inc. held a total portfolio value of $99.1B, covering 42 public equity positions.
During Q2 2024, Alphabet Inc.'s portfolio maintained high stability with no major positional turnover, reflecting a continuous long-term holding approach.
In terms of portfolio concentration, the top 5 core holdings (including GTLB, ARM, RVMD) accounted for 1.3% of total reported equity market value during Q2 2024.
| # | Ticker | Issuer | Asset Subclass | Weight | Weight Change | Shares Change | 4Q Trend |
|---|---|---|---|---|---|---|---|
| 1 | GTLB | Gitlab Inc-cl A | Stock-Tech | 24.58% | -1.39% | — | |
| 2 | ARM | Arm Holdings Plc-adr | Stock-Tech | 16.25% | -6.69% | — | |
| 3 | RVMD | Revolution Medicines Inc | Stock-Healthcare | 10.43% | -7.41% | +0.10% | |
| 4 | CRWD | Crowdstrike Holdings Inc - A | Stock-Tech | 8.31% | — | -50.00% | |
| 5 | FRSH | Freshworks Inc-cl A | Stock-Other | 7.93% | -3.07% | — | |
| 6 | DXCM | Dexcom Inc | Stock-Healthcare | 5.96% | — | -42.10% | |
| 7 | PATH | Uipath Inc - Class A | Stock-Tech | 4.52% | -1.86% | — | |
| 8 | PRME | Prime Medicine Inc | Stock-Other | 3.92% | -1.38% | — | |
| 9 | SNOW | Snowflake Inc | Stock-Tech | 3.66% | — | — | |
| 10 | ✓ | Verve Therapeutics Inc | Stock-Other | 3.05% | — | — | |
| 11 | PL | Planet Labs Pbc | Stock-Industrials | 3.01% | -23.35% | — | |
| 12 | TEM | Tempus Ai Inc-cl A | Stock-Healthcare | 2.75% | -1.66% | — | |
| 13 | SANA | Sana Biotechnology Inc | Stock-Other | 0.78% | -0.19% | — | |
| 14 | RLAY | Relay Therapeutics Inc | Stock-Other | 0.52% | -0.36% | — | |
| 15 | VERA | Vera Therapeutics Inc | Stock-Other | 0.44% | -0.23% | — | |
| 16 | LYEL | Lyell Immunopharma, Inc. | Stock-Other | 0.43% | — | — | |
| 17 | OSCR | Oscar Health Inc - Class A | Stock-Healthcare | 0.39% | -0.13% | — | |
| 18 | BEAM | Beam Therapeutics Inc | Stock-Other | 0.38% | -0.18% | — | |
| 19 | TCRX | Tscan Therapeutics Inc | Stock-Other | 0.32% | — | — | |
| 20 | ILMN | Illumina Inc | Stock-Healthcare | 0.28% | — | — | |
| 21 | GLUE | Monte Rosa Therapeutics Inc | Stock-Other | 0.28% | -0.27% | — | |
| 22 | DNTH | Dianthus Therapeutics Inc | Stock-Other | 0.27% | — | — | |
| 23 | DM* | Desktop Metal Inc-a | Stock-Other | 0.23% | — | — | |
| 24 | FHTX | Foghorn Therapeutics Inc | Stock-Other | 0.15% | — | — | |
| 25 | TNYA | Tenaya Therapeutics Inc | Stock-Other | 0.14% | -0.02% | EXIT | |
| 26 | GUTS | Fractyl Health Inc | Stock-Other | 0.14% | — | — | |
| 27 | AUTL | Autolus Therapeutics PLC | Stock-Other | 0.12% | -0.02% | — | |
| 28 | ✓ | Stock-Other | 0.12% | — | — | ||
| 29 | BRNS | Barinthus Biotherapeutics Pl | Stock-Other | 0.11% | — | — | |
| 30 | KRON1USD | Kronos Bio Inc | Stock-Other | 0.09% | — | — | |
| 31 | RANI | Rani Therapeutics Holdings-a | Stock-Other | 0.09% | — | — | |
| 32 | ✓ | Rapt Therapeutics Inc | Stock-Other | 0.08% | — | — | |
| 33 | TSHA | Taysha Gene Therapies Inc | Stock-Other | 0.07% | — | — | |
| 34 | SPRO | Spero Therapeutics Inc | Stock-Other | 0.06% | -0.05% | — | |
| 35 | EXK | Exact Sciences CORP | Stock-Materials | 0.05% | — | — | |
| 36 | ALEC | Alector Inc | Stock-Other | 0.04% | — | — | |
| 37 | HYPR | Hyperfine Inc | Stock-Other | 0.04% | -0.02% | — | |
| 38 | QNCX | Quince Therapeutics, Inc. | Stock-Other | 0.01% | — | — | |
| 39 | FULC | Fulcrum Therapeutics Inc | Stock-Other | — | — | — | |
| 40 | RGEN | Repligen CORP | Stock-Healthcare | — | — | — | |
| 41 | HLTHQ | Cue Health Inc | Stock-Other | — | — | — | |
| 42 | NVTA1EUR | Invitae CORP | Stock-Other | — | — | — |
According to official SEC Form 13F filings, Alphabet Inc. reported a total U.S. public equity portfolio value of $99.1B across 42 disclosed positions in Q2 2024.
During Q2 2024, Alphabet Inc.'s top holdings by market value included GTLB (24.6%)、ARM (16.3%)、RVMD (10.4%). The largest single position, GTLB, represented 24.6% of total portfolio value.
Expert Analysis & Guides for Tracking Wall Street Smart Money Movements
Learn how SEC Form 13F filings work, the $100M threshold, 45-day reporting lag, and how to track top hedge fund holdings.
In Q2 2024, Alphabet Inc. made 0 total portfolio adjustments, initiating 0 new buys, adding to 0 positions, trimming 0 holdings, and fully liquidating 0 stocks.
All holding records on this page are fetched directly from the U.S. Securities and Exchange Commission (SEC) EDGAR system (Form 13F-HR). AlphaSMO parses CUSIP identifiers and formats data into Schema.org-compliant datasets.
Understand SEC Form 4 insider disclosures for corporate officers, directors, and 10% owners to track executive transactions.
Understand Rule 144 restricted stock sale notices to spot planned insider liquidations before market sell pressure arrives.
Explore the 5% beneficial ownership threshold, 13D vs 13G filing differences, and recent SEC accelerated deadline rules.
Best practices for analyzing 13F quarterly changes without getting misled by stock splits, options, or market valuation drift.
Learn how AlphaSMO's flagship signal detects high-conviction stocks where 13F hedge funds and corporate insiders buy at the same time.